Cargando…

A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned

Availability of integrase strand transfer inhibitors created interest in determining whether their use would decrease persistently infected cell numbers. This study hypothesized that adding raltegravir (RAL) to standard antiretroviral therapy (ART) would decrease human immunodeficiency virus (HIV)-i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Collier, Ann C., Chun, Tae-Wook, Maenza, Janine, Coombs, Robert W., Tapia, Kenneth, Chang, Ming, Stevens, Claire E., Justement, J. Shawn, Murray, Danielle, Stekler, Joanne D., Mullins, James I, Holte, Sarah E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2016
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744890/ https://www.ncbi.nlm.nih.gov/pubmed/26862469 http://dx.doi.org/10.1089/biores.2015.0038

Ejemplares similares

Prevalence and Impact of Minority Variant Drug Resistance Mutations in Primary HIV-1 Infection
por: Stekler, Joanne D., et al.
Publicado: (2011)

Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort
por: Stekler, Joanne D., et al.
Publicado: (2018)

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment
por: Aamer, Hadega A., et al.
Publicado: (2020)

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
por: Chirch, Lisa M, et al.
Publicado: (2010)

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
por: Cozzi‐Lepri, A, et al.
Publicado: (2017)

Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction
por: Ostrowski, Mario, et al.
Publicado: (2015)

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2015)

Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir
por: Ouyang, Zhengyu, et al.
Publicado: (2015)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy
por: Li, Jonathan Z., et al.
Publicado: (2014)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Cytokine secretion from brain macrophages infected with human immunodeficiency virus in vitro and treated with raltegravir
por: Tatro, Erick T, et al.
Publicado: (2014)

Intensification of antiretroviral treatment with raltegravir for pregnant women living with HIV at high risk of vertical transmission
por: Puthanakit, Thanyawee, et al.
Publicado: (2018)

Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant Women
por: Cecchini, Diego M., et al.
Publicado: (2017)

2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir
por: Hsu, Ricky, et al.
Publicado: (2019)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial
por: Kityo, Cissy, et al.
Publicado: (2018)

Optimising neonatal antiretroviral therapy using raltegravir: a qualitative analysis of healthcare workers’ and caregivers’ perspectives
por: Katirayi, Leila, et al.
Publicado: (2022)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Raltegravir in treatment naïve patients
por: Cossarini, F, et al.
Publicado: (2009)

Raltegravir use in special populations
por: Johnson, Margaret
Publicado: (2009)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy
por: Lewis, Mark G, et al.
Publicado: (2010)

Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy
por: Delagreverie, Héloïse M, et al.
Publicado: (2020)

A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance
por: Bañón, Sara, et al.
Publicado: (2014)

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
por: Bercoff, Danielle Perez, et al.
Publicado: (2010)

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
por: Riccardi, Niccolò, et al.
Publicado: (2019)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

Spectrophotometric Estimation of Raltegravir Potassium in Tablets
por: Kore, P. P., et al.
Publicado: (2014)

Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina
por: Rombini, Fernanda, et al.
Publicado: (2020)

Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature
por: Ceccarelli, Giancarlo, et al.
Publicado: (2011)

Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers
por: Barroso, Sergio, et al.
Publicado: (2019)

Superior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design
por: Kunwar, Pratima, et al.
Publicado: (2013)

Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection
por: Rosenberg, Eric S., et al.
Publicado: (2010)

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
por: Gandhi, Rajesh T., et al.
Publicado: (2010)

Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro
por: Xu, Peipei, et al.
Publicado: (2017)

1617 Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents – a 24 Week Study
por: Teppler, Hedy, et al.
Publicado: (2014)

Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study
por: Troya, Jesús, et al.
Publicado: (2018)

Predicting poor adherence to antiretroviral therapy among treatment-naïve veterans infected with human immunodeficiency virus
por: Cheng, Yan, et al.
Publicado: (2018)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_66s7mr1jcfqrapb2e4645at2l7